Surviving Melanoma in Europe.
Access to prevention, early detection and effective treatment for all.
Melanoma Patient Network Europe
MPNE WORKSHOP 22nd- 25th November 2018
Krusenberg Herrgård is a friendly conference center
and hotel at the lake Mälaren, a 25 min drive away from Stockholm Arlanda, Sweden's main airport.
We thank for their support
The small print
Decisions about workshop participation will be based on suitability for the workshop as well as scope of the Melanoma patient network Europe and are final.
22nd November- 25th November 2018
please note that this workshop already starts on THURSDAY
Krusenberg Herrgård, Uppsala, Sweden
Why this workshop?
Adding a price tag to a life seems unethical. At the same time, limited healthcare budgets and delays in access to potentially life-saving therapies are a dire part of Melanoma reality and directly decide who gets a least a chance to survive. And who doesn't.
We as Melanoma patient advocates need to be actively involved in finding solutions that save the lives of Melanoma patients AND that respect the needs of our societies. This workshop attempts to shine light on a few different perspectives around healthcare economics, resource allocation and attempts at cost control. Understanding every party's constraints and reasoning is the start!
Join us to tackle questions like these
What are the economic constraints a healthcare system is facing? What is 'value' for a healthcare system? What is 'value' for a Melanoma patient? How do we measure that? And what happens when it takes too long to measure? And how can we be fair across our entire societies and not only for small groups of people? What is a 'fair' price? And what are the intended- and unintended- consequences of certain economically motivated decisions?
Dr. Christopher McCabe is the Executive Director and CEO of the Institute of Health Economics (IHE).
Dr. McCabe brings more than 25 years of experience as an internationally recognized health economist to his role with the organization. He was more recently a Professor of Health Economics at the University of Alberta, where he was appointed Capital Health Endowed Research Chair at the University of Alberta, leading two Genome Canada research groups focused on the evaluation, adoption and implementation of Precision Medicine technologies. He also served on the Canadian Agency for Drugs and Technologies in Health Care (CADTH) Health Economics Working Group, which authored the 4th Edition of the CADTH Guidelines for the Economic Evaluation of Health Technologies earlier this year.
Prior to his work in Canada, Dr. McCabe was appointed to the Chair in Health Economics at the University of Leeds in 2007, and went on to be the Founding Director of the Academic Unit of Health Economics within the Leeds Institute of Health Science. He has also held Chairs in Health Economics at the Universities of Warwick and Sheffield.
Starting in the early 2000’s, Dr. McCabe worked extensively with the U.K.’s National Institute for Health and Care Excellence (NICE); initially as team leader on the technology appraisal of disease modifying drugs for multiple sclerosis and subsequently as the Founding Director of the NICE Decision Support Unit. He was an expert advisor to the 2008 Edition of the NICE Guide to the Methods of Technology Appraisal, and a member of the writing group for the previous edition in 2003. Dr. McCabe also served as a member of the NICE Medical Technologies Advisory Committee. Prior to his work with NICE, Dr. McCabe worked with local commissioners from U.K.’s National Health Service (NHS), evaluating new technologies to inform funding decisions.
Dr. McCabe received his PhD in Health Economics at the University of Sheffield in the U.K.
Karolinska Institutet, Stockholm
biography to come
Who should apply?
This workshop is directed at MPNEhubs, European Melanoma advocates who want to connect between their own country and the European Melanoma community- we are looking for advocates with a keen interest to share, work together and put in the effort before, during and after the workshop to produce concrete results for our network!
The number of participants is limited to 30 advocates to ensure effective exchange. A good enough working knowledge of English is essential to participate in the discussions!
How does it work?
1. Application: Attendance of this workshop is upon application only.
2. Selection: The organising committee will select participants based on their motivation with regards to access to innovative therapies in Melanoma, experience in collaboration and exchange and their level of English. As always, we are aiming for a balanced European mix!
3. Acceptance: Selected applicants will need to accept their place at the workshop and agree to
4. Accommodation: registration, accommodation and workshop meals will be arranged by MPNE and are free for selected advocates during the workshop (Friday and Saturday night).
5. Travel: Advocates however need to arrange their own travel- please wait until you have heard from us before booking. We are able to provide a travel allowance up to 400 Euro for economy/ 2nd class travel after the event and against original receipts only.
6. Extras: Please note that extras at the hotel, additional nights as well bank fees are at your own expenses and will not be covered by MPNE.
Gilliosa Spurrier, Mélanome France and MPNE
Violeta Astratinei, Stichting Melanoom, Melanoma Romania and MPNE
Bettina Ryll, MPNE
Last update 3rd September 2018 BR
Workshop participation, travel
and full-board accommodation
will be free for participants.
Participation is upon application only.